Evaluation of Therapeutic Response Under Biologic Therapy in Patients with Rheumatoid Arthritis

Authors

  • Badia Djebbar Doctor of pharmacy, intern at immunology laboratory of UHU (hospital-university unit) Hassiba Ben Bouali and functional rehabilitation service at CHU (hospital-university center) Frantz Fanon Blida, Algeria https://orcid.org/0009-0009-4795-2344
  • Mohamed Lotfi BOUDJELLA Assistant Professor, head of the Immunology Unit at UHU Hassiba Ben Bouali Blida, Algeria

Abstract

Biotherapy has revolutionized the therapeutic management of rheumatoid arthritis (RA). The objective of the study was to evaluate and compare the efficacy and tolerance of biological disease modifying antirheumatic drugs (bDMARDs) and conventional disease modifying antirheumatic drugs ( cDMARDs) used in RA.

It was a retrospective study covering 13 years at the level of the immunology unit of the UHU Hassiba Ben Bouali Blida and functional rehabilitation service of the CHU Frantz Fanon Blida. We identified 1866 records of patients with RA, 75 receiving biotherapy and 71 receiving conventional treatment. The therapeutic response was evaluated by the DAS 28-ESR (disease activity score based on erythrocyte sedimentation rate) and interpreted according to the EULAR (European league against rheumatism) judgements criteria.

A female predominance of 83%, the average age of RA patients was 49.3 ±13.42 years, the mean starting DAS28-ESR was 5.625± 1.4. 84% of patients initially received MTX (methotrexate) on the front line, the decrease in DAS28-ESR was non- significant, with patients exhibiting intolerance (41%), and (45%) ineffectiveness. The introduction of biotherapy mainly Actemra allowed a decrease of DAS28-ESR of - 1.842±0.3812, a significant decrease according to the criteria of the EULAR. Humira had an adverse efficacy and tolerance profile (including the occurrence of severe adverse effects (AEs)).

In conclusion, biotherapy is more effective than conventional treatments, while in terms of tolerance data are insufficient to make a judgment on it.

Keywords: Rheumatoid arthritis – Biotherapy.

Keywords:

Rheumatoid arthritis, Biotherapy

DOI

https://doi.org/10.22270/jddt.v14i2.6404

Author Biographies

Badia Djebbar, Doctor of pharmacy, intern at immunology laboratory of UHU (hospital-university unit) Hassiba Ben Bouali and functional rehabilitation service at CHU (hospital-university center) Frantz Fanon Blida, Algeria

Doctor of pharmacy, intern at immunology laboratory of UHU (hospital-university unit) Hassiba Ben Bouali and functional rehabilitation service at CHU (hospital-university center) Frantz Fanon Blida, Algeria

Mohamed Lotfi BOUDJELLA, Assistant Professor, head of the Immunology Unit at UHU Hassiba Ben Bouali Blida, Algeria

Assistant Professor, head of the Immunology Unit at UHU Hassiba Ben Bouali Blida, Algeria

References

Radu, A.-F.; Bungau, S.G. Management of Rheumatoid Arthritis: An Overview. Cells 2021, 10, 2857. https://doi.org/10.3390/cells10112857

Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. J Auto-immune. 2020 Jun;110:102400. https://doi.org/10.1016/j.jaut.2019.102400

Boissier M-C, Biton J, Semerano L, Decker P, Bessis N. L’origine de la polyarthrite rhumatoïde. Revue du Rhumatisme. 2019;86:A19-A24. http://dx.doi.org/10.1016/S1169-8330(19)30353-9

Benjamin O, Goyal A, Lappin SL. Disease modifying anti-rheumatic drugs (DMARD). 2018. PMID: 29939640.

Bouaddi I, El Badri D, Hassani A, Bahouque H, Rkain H, Allali F, et al. Les critères d’évaluation de la polyarthrite rhumatoïde. Rev Mar Rhum. 2012;19:19-23. http://dx.doi.org/10.24398/a.122.2012

Hmamouchi I, Combe B, Fautrel B, Rincheval N, Lukas C. Prévalence et concordance de la rémission précoce et prolongée évaluée par différents indices validés de la cohorte d’arthrites débutantes «ESPOIR». Revue du Rhumatisme. 2015;82(1):47-53. https://doi.org/10.1016/j.rhum.2014.04.001

Gaujoux-Viala C, Gossec L, Cantagrel A, Dougados M, Fautrel B, Mariette X, et al. Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. Revue du rhumatisme. 2014;81(4):303-12. https://doi.org/10.1016/j.rhum.2014.04.009

Hua C, Daien CI, Combe B, Landewe R. Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD open. 2017;3(1):e000406. https://doi.org/10.1136/rmdopen-2016-000406

Daien C, Hua C, Gaujoux-Viala C, Cantagrel A, Dubremetz M, Dougados M, et al. Actualisation des Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. Revue du rhumatisme. 2019;86(1):8-24. https://doi.org/10.1016/j.rhum.2018.09.008

Brahem M, Sarraj R, Grassa R, Amani B, Hachfi H, Younes M. Les facteurs prédictifs de l’intolérance au méthotrexate au cours de la polyarthrite rhumatoïde. Revue du Rhumatisme. 2021;88:A298-A9. https://doi.org/10.1016/j.rhum.2021.10.510

Oulkadi L, Rostom S, Hmamouchi I, Binoune IE, Amine B, Abouqal R, Achemlal L, Allali F, Bouchti IE, Maghraoui AE, Ghozlani I, Hassikou H, Harzy T, Ichchou L, Mkinsi O, Niamane R, Bahiri R. Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR Study. Mediterr J Rheumatol. 2022 Jun 30;33(2):224-231. https://doi.org/10.31138%2Fmjr.33.2.224

Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nature Reviews Rheumatology. 2016;12(12):731-42. https://doi.org/10.1038/nrrheum.2016.175

Inotai A, Rojkovich B, Fülöp A, Jászay E, Ágh T, Mészáros Á. Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. Rheumatology international. 2012;32:963-9. https://doi.org/10.1007/s00296-010-1721-x

Pers Y-M, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology. 2014;53(1):76-84. https://doi.org/10.1093/rheumatology/ket301

Codreanu C, Mogosan C, Ionescu R, Ancuta I, Opris D. Biologic therapy in rheumatoid arthritis: results from the Romanian registry of rheumatic diseases one year after initiation. Farmacia. 2014;62(6):1089-96. DOI: 10.37897/RJR.2020.2.2.

Divonne MdlF, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers. Joint Bone Spine. 2017;84(2):133-40. https://doi.org/10.1016/j.jbspin.2016.02.028

Cacciapaglia F, Venerito V, Stano S, Fornaro M, Lopalco G, Iannone F. Comparison of adalimumab to other targeted therapies in rheumatoid arthritis: results from systematic literature review and meta-analysis. Journal of Personalized Medicine. 2022;12(3):353. https://doi.org/10.3390/jpm12030353

Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo RM, et al. Taux de rétention de l’adalimumab, de l’étanercept et de l’infliximab en 1re ou 2e ligne de biothérapie chez les patients atteints de polyarthrite rhumatoïde en pratique courante. Revue du rhumatisme. 2014;81(6):483-90. https://doi.org/10.1016/j.rhum.2014.07.001

Hagege O, Lequerre T, Marcelli C, Varin R, Alcaix D, Weber A, et al. AB1615 EVALUATION OF THE NOCEBO EFFECT WHEN SWITCHING FROM THE ORIGINATOR MOLECULE TO A BIOSIMILAR IN A NORMANDY RETROSPECTIVE COHORT OF PATIENTS WITH INFLAMMATORY RHEUMATISM TREATED WITH ETANERCEPT OR ADALIMUMAB (BIONORIC STUDY). BMJ Publishing Group Ltd; 2023. https://doi.org/10.1136/annrheumdis-2023-eular.4416

Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet (London, England). 2013;381(9877):1541-50. https://doi.org/10.1016/s0140-6736(13)60250-0

Ediriweera A, Aung T, Savanovic-Abel O. AB0408 DESCRIPTIVE STUDY ON USE OF BIOSIMILARS IN RHEUMATOID ARTHRITIS IN UNIVERSITY HOSPITALS PLYMOUTH, UNITED KINGDOM. BMJ Publishing Group Ltd; 2023. https://doi.org/10.1136/annrheumdis-2023-eular.2165

Lechat P. Médicaments biosimilaires: enjeux réglementaires et impacts médicoéconomiques. Bulletin de l'Académie Nationale de Médecine. 2020;204(8):877-83. https://doi.org/10.1016%2Fj.banm.2020.07.050

Akasbi N, Mounir A, Bakale FEO, El Fakir S, Harzy T. TOCILIZUMAB: EFFICACITE ET TOLERANCE DANS LA POLYARTHRITE RHUMATOÏDE EN PRATIQUE COURANTE. Integrative Journal of Medical Sciences. 2019;6:1-5. http://dx.doi.org/10.15342/ijms.v6ir.253

Genovese MC, Glover J, Greenwald M, Porawska W, El Khouri EC, Dokoupilova E, et al. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, phase III, double-blind study, and its open-label extension. Arthritis research & therapy. 2019;21(1):1-12. https://doi.org/10.1186/s13075-019-2046-0

Montero-Vilchez T, Cuenca-Barrales C, Rodriguez-Tejero A, Martinez-Lopez A, Arias-Santiago S, Molina-Leyva A. Switching from adalimumab originator to biosimilar: clinical experience in patients with hidradenitis suppurativa. Journal of Clinical Medicine. 2022;11(4):1007. https://doi.org/10.3390/jcm11041007

Wu Y-F, Shin Y-C, Yang C-H, Huang Y-H. Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: An open-label, retrospective, observational study in Taiwan. Dermatologica Sinica. 2013;31(2):49-53. http://dx.doi.org/10.1016/j.dsi.2012.09.001

Aouatef BF, Zohra GBF. Médicaments biosimilaires: entre évolution de la règlementation et… bon sens. Algerian Journal of Health Sciences. 2019;1(01):54-61.

Amgevita January 18, 2023 [Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita

Solymbic 2019 [Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/solymbic.

Goel N, Chance K. Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology. 2017;56(2):187-97. https://doi.org/10.1093/rheumatology/kew206

Published

15-02-2024
Statistics
Abstract Display: 224
PDF Downloads: 178
PDF Downloads: 14

How to Cite

1.
Djebbar B, BOUDJELLA ML. Evaluation of Therapeutic Response Under Biologic Therapy in Patients with Rheumatoid Arthritis. J. Drug Delivery Ther. [Internet]. 2024 Feb. 15 [cited 2025 Feb. 19];14(2):53-8. Available from: https://jddtonline.info/index.php/jddt/article/view/6404

How to Cite

1.
Djebbar B, BOUDJELLA ML. Evaluation of Therapeutic Response Under Biologic Therapy in Patients with Rheumatoid Arthritis. J. Drug Delivery Ther. [Internet]. 2024 Feb. 15 [cited 2025 Feb. 19];14(2):53-8. Available from: https://jddtonline.info/index.php/jddt/article/view/6404